Xenbase Image ID: 81923

Fig. 4. Validation of the effect knocking down MyoD on shortlisted targets. Embryos were injected unilaterally with 10 ng of Morpholino A and 30 ng of Morpholino B (knock-down), 2.5 ng XtMyoD mRNA (overexpression) or both (rescue). Control embryos were injected with the equivalent amount of control MO. The injected side is shown by an asterisk. Numbers and percentages indicate the number of embryos with the phenotype shown. Numbers are from several experiments. The knock-down of MyoD protein causes the loss of expression of all shortlisted targets. Overexpression of MyoD up-regulates the expression of most targets, with the exception of Myf5. Target expression is rescued effectively for all targets when XtMyoD mRNA is coinjected with morpholino. Xbra is expressed in all mesoderm and is included as a control. Embryos have been analysed at mid-gastrula NF stage 11.5 and are viewed vegetally. For numbers and statistical analysis see Supplementary data Table S1. Image published in: Maguire RJ et al. (2012) Copyright © 2012. Image reproduced with permission of the Publisher, Elsevier B. V. Gene Synonyms Species Stage(s) Tissue hes5.L esr-1, esr1, hes5.1, XESR-1 X. laevis Throughout NF stage 11.5 mesoderm involuted ventral mesoderm hes5.L esr-1, esr1, hes5.1, XESR-1 X. laevis Throughout NF stage 11.5 mesoderm involuted ventral mesoderm foxc1.S fkhl7, foxc1-a, foxc1-b, freac-3, freac3, igda, ihg1, irid1, rieg3, xfd-11 X. laevis Throughout NF stage 11.5 mesoderm involuting marginal zone msgn1.L mes1, mesogenin, MesP-related bHLH factor, Mespo, msgn1-a, msgn1-b, pMesogenin1 X. laevis Throughout NF stage 11.5 mesoderm involuting marginal zone myf5.L myf-5, Xmyf-5, Xmyf5 X. laevis Throughout NF stage 11.5 mesoderm involuted dorsal mesoderm tbx6.L XTbx6 X. laevis Throughout NF stage 11.5 mesoderm involuted dorsal mesoderm Image source: Published Experiment + Assay Source Phenotypes and Disease Xla Wt + myod1 + NF11.5 (in situ hybridization) fig.4.a Expression Phenotype mislocalised esr1.L expression in mesoderm increased amount esr1.L expression in mesoderm Xla Wt + myod1 MO + NF11.5 (in situ hybridization) fig.4.a Expression Phenotype decreased amount esr1.L expression in mesoderm Xla Wt + myod1 + NF11.5 (in situ hybridization) fig.4.b Expression Phenotype increased amount esr2.L expression in mesoderm Xla Wt + myod1 MO + NF11.5 (in situ hybridization) fig.4.b Expression Phenotype decreased amount esr2.L expression in mesoderm Xla Wt + myod1 + NF11.5 (in situ hybridization) fig.4.c Expression Phenotype increased amount foxc1.S expression in mesoderm Xla Wt + myod1 MO + NF11.5 (in situ hybridization) fig.4.c Expression Phenotype decreased amount foxc1.S expression in mesoderm Xla Wt + myod1 + NF11.5 (in situ hybridization) fig.4.d Expression Phenotype increased amount msgn1.L expression in mesoderm Xla Wt + myod1 MO + NF11.5 (in situ hybridization) fig.4.d Expression Phenotype decreased amount msgn1.L expression in mesoderm Xla Wt + myod1 MO + NF11.5 (in situ hybridization) fig.4.e Expression Phenotype decreased amount myf5.L expression in mesoderm Xla Wt + myod1 + NF11.5 (in situ hybridization) fig.4.f Expression Phenotype increased amount rbm24.L expression in mesoderm Xla Wt + myod1 MO + NF11.5 (in situ hybridization) fig.4.f Expression Phenotype decreased amount rbm24.L expression in mesoderm Xla Wt + myod1 + NF11.5 (in situ hybridization) fig.4.g Expression Phenotype increased amount tbx6.L expression in mesoderm Xla Wt + myod1 MO + NF11.5 (in situ hybridization) fig.4.g Expression Phenotype decreased amount tbx6.L expression in mesoderm Larger Image Printer Friendly View

Return to previous page